What is Avita Medical Inc's earnings per share (EPS)?

Avita Medical Inc (RCEL) reported diluted earnings per share of $-1.74 for fiscal year 2025. This represents a 27.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Avita Medical Inc Financials

RCEL

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Avita Medical Inc (RCEL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 15/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Avita Medical Inc has an operating margin of -59.4%, meaning the company retains $-59 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -88.1% the prior year.

Growth

Avita Medical Inc's revenue grew 11.5% year-over-year to $71.6M, a solid pace of expansion. This earns a growth score of 52/100.

Liquidity

Avita Medical Inc's current ratio of 0.57 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 6/100, which could limit financial flexibility.

Cash Flow

While Avita Medical Inc generated -$31.2M in operating cash flow, capex of $1.0M consumed most of it, leaving -$32.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

3/9

Avita Medical Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.64x

For every $1 of reported earnings, Avita Medical Inc generates $0.64 in operating cash flow (-$31.2M OCF vs -$48.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-8.5x

Avita Medical Inc earns $-8.5 in operating income for every $1 of interest expense (-$42.5M vs $5.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$71.6M

YoY+11.5%

5Y CAGR+38.1%

Avita Medical Inc generated $71.6M in revenue in fiscal year 2025. This represents an increase of 11.5% from the prior year.

EBITDA

-$40.2M

YoY+27.5%

Avita Medical Inc's EBITDA was -$40.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 27.5% from the prior year.

Net Income

-$48.6M

YoY+21.4%

Avita Medical Inc reported -$48.6M in net income in fiscal year 2025. This represents an increase of 21.4% from the prior year.

EPS (Diluted)

$-1.74

YoY+27.2%

Avita Medical Inc earned $-1.74 per diluted share (EPS) in fiscal year 2025. This represents an increase of 27.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$32.2M

YoY+44.6%

Avita Medical Inc generated -$32.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 44.6% from the prior year.

Cash & Debt

$10.2M

YoY-27.1%

5Y CAGR-32.6%

Avita Medical Inc held $10.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

31M

YoY+16.2%

5Y CAGR+7.4%

Avita Medical Inc had 31M shares outstanding in fiscal year 2025. This represents an increase of 16.2% from the prior year.

Margins & Returns

Gross Margin

82.1%

YoY-3.7pp

5Y CAGR+3.0pp

Avita Medical Inc's gross margin was 82.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.7 percentage points from the prior year.

Operating Margin

-59.4%

YoY+28.7pp

5Y CAGR+239.8pp

Avita Medical Inc's operating margin was -59.4% in fiscal year 2025, reflecting core business profitability. This is up 28.7 percentage points from the prior year.

Net Margin

-67.8%

YoY+28.4pp

5Y CAGR+226.8pp

Avita Medical Inc's net profit margin was -67.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 28.4 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$20.8M

YoY+2.4%

5Y CAGR+17.9%

Avita Medical Inc invested $20.8M in research and development in fiscal year 2025. This represents an increase of 2.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.0M

YoY-89.0%

5Y CAGR+11.2%

Avita Medical Inc invested $1.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.0% from the prior year.

RCEL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$71.6M+11.5%	$64.3M+28.1%	$50.1M+45.7%	$34.4M+17.8%	$29.2M+104.9%	$14.3M
Cost of Revenue	$12.8M+40.7%	$9.1M+16.9%	$7.8M+28.8%	$6.0M+1.5%	$5.9M+100.1%	$3.0M
Gross Profit	$58.8M+6.6%	$55.2M+30.2%	$42.4M+49.3%	$28.4M+21.9%	$23.3M+106.2%	$11.3M
R&D Expenses	$20.8M+2.4%	$20.4M-2.2%	$20.8M+50.3%	$13.9M-6.5%	$14.8M+61.7%	$9.2M
SG&A Expenses	$27.4M-17.5%	$33.2M+17.2%	$28.3M+21.4%	$23.3M+4.2%	$22.4M-32.2%	$33.0M
Operating Income	-$42.5M+24.8%	-$56.6M-32.7%	-$42.7M-55.1%	-$27.5M-3.6%	-$26.5M+37.8%	-$42.7M
Interest Expense	$5.0M-6.7%	$5.4M+369.0%	$1.1M+7043.8%	$16K-27.3%	$22K-33.3%	$33K
Income Tax	$11K-79.6%	$54K-18.2%	$66K+83.3%	$36K-5.3%	$38K+850.0%	$4K
Net Income	-$48.6M+21.4%	-$61.8M-74.8%	-$35.4M-32.7%	-$26.7M-0.3%	-$26.6M+36.8%	-$42.0M
EPS (Diluted)	$-1.74+27.2%	$-2.39-70.7%	$-1.40-230.8%	$1.07-8.5%	$1.17-43.5%	$2.07

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$17.6M+3.2%	$17.1M-7.4%	$18.4M-0.5%	$18.5M+0.6%	$18.4M-5.8%	$19.5M+28.6%	$15.2M+36.8%	$11.1M
Cost of Revenue	$3.3M+3.7%	$3.2M-8.1%	$3.5M+22.4%	$2.8M+24.3%	$2.3M-28.5%	$3.2M+51.1%	$2.1M+39.5%	$1.5M
Gross Profit	$14.3M+3.1%	$13.9M-7.2%	$14.9M-4.7%	$15.7M-2.8%	$16.1M-1.4%	$16.4M+25.0%	$13.1M+36.4%	$9.6M
R&D Expenses	$5.7M+51.8%	$3.7M-26.8%	$5.1M-18.6%	$6.3M+29.5%	$4.9M-10.6%	$5.4M+11.1%	$4.9M-5.9%	$5.2M
SG&A Expenses	$7.1M-1.9%	$7.2M+8.4%	$6.7M+4.3%	$6.4M-10.3%	$7.1M-25.7%	$9.6M+27.5%	$7.5M-16.1%	$9.0M
Operating Income	-$10.4M-13.7%	-$9.2M+17.9%	-$11.1M+5.7%	-$11.8M-18.8%	-$10.0M+27.9%	-$13.8M+11.6%	-$15.6M+9.2%	-$17.2M
Interest Expense	$1.3M-1.3%	$1.3M+1.3%	$1.3M+1.5%	$1.2M-5.1%	$1.3M-4.4%	$1.4M+0.9%	$1.3M-0.7%	$1.4M
Income Tax	-$16K-206.7%	$15K+275.0%	$4K-50.0%	$8K-57.9%	$19K+167.9%	-$28K-184.8%	$33K+10.0%	$30K
Net Income	-$11.6M+11.9%	-$13.2M-32.9%	-$9.9M+28.4%	-$13.9M-19.6%	-$11.6M+28.5%	-$16.2M-5.3%	-$15.4M+17.5%	-$18.7M
EPS (Diluted)	N/A	$-0.46-21.1%	$-0.38+28.3%	$-0.53	N/A	$-0.62-3.3%	$-0.60+17.8%	$-0.73

RCEL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$56.4M-29.3%	$79.7M-28.6%	$111.6M+13.6%	$98.3M-21.7%	$125.5M+52.2%	$82.5M
Current Assets	$35.5M-37.7%	$57.0M-45.2%	$104.0M+18.9%	$87.5M-27.9%	$121.3M+54.8%	$78.4M
Cash & Equivalents	$10.2M-27.1%	$14.1M-36.5%	$22.1M+21.8%	$18.2M-83.6%	$110.7M+50.4%	$73.6M
Inventory	$6.9M-4.7%	$7.3M+29.9%	$5.6M+163.3%	$2.1M+29.0%	$1.6M+46.4%	$1.1M
Accounts Receivable	$9.1M-22.9%	$11.8M+53.8%	$7.7M+118.0%	$3.5M+1.4%	$3.5M+67.0%	$2.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$73.0M-2.6%	$75.0M+21.1%	$61.9M+377.3%	$13.0M+31.7%	$9.8M-2.1%	$10.1M
Current Liabilities	$62.7M+210.9%	$20.2M+52.7%	$13.2M+23.4%	$10.7M+44.7%	$7.4M-4.1%	$7.7M
Long-Term Debt	$0-100.0%	$42.2M+6.1%	$39.8M	N/A	N/A	N/A
Total Equity	-$16.6M-470.1%	$4.5M-90.8%	$49.1M-42.1%	$84.7M-26.7%	$115.7M+59.7%	$72.4M
Retained Earnings	-$408.4M-13.5%	-$359.8M-20.8%	-$298.0M-13.5%	-$262.6M-18.6%	-$221.5M-13.6%	-$194.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$56.4M-11.5%	$63.7M+9.6%	$58.1M-16.4%	$69.6M-12.7%	$79.7M-1.7%	$81.1M-7.7%	$87.8M-9.8%	$97.4M
Current Assets	$35.5M-14.2%	$41.4M+14.1%	$36.3M-24.4%	$48.0M-15.8%	$57.0M-10.8%	$63.9M-12.4%	$73.0M-15.2%	$86.0M
Cash & Equivalents	$10.2M-33.6%	$15.4M+26.2%	$12.2M-17.8%	$14.9M+5.8%	$14.1M-24.6%	$18.6M+6.8%	$17.5M+3.0%	$17.0M
Inventory	$6.9M-4.3%	$7.2M-3.9%	$7.5M-10.2%	$8.4M+15.5%	$7.3M+16.7%	$6.2M-7.2%	$6.7M-6.4%	$7.2M
Accounts Receivable	$9.1M+0.8%	$9.0M-20.5%	$11.3M-5.8%	$12.0M+2.2%	$11.8M+14.6%	$10.3M+18.0%	$8.7M+23.1%	$7.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$73.0M+3.8%	$70.4M-0.8%	$71.0M-4.2%	$74.1M-1.2%	$75.0M+9.3%	$68.6M+8.0%	$63.5M-0.7%	$64.0M
Current Liabilities	$62.7M+1.4%	$61.8M-1.2%	$62.6M+172.7%	$23.0M+13.9%	$20.2M+17.6%	$17.1M+24.3%	$13.8M+16.2%	$11.9M
Long-Term Debt	$0	$0-100.0%	$42.2M+1.8%	$41.5M-1.8%	$42.2M-0.7%	$42.5M+3.8%	$41.0M-0.8%	$41.3M
Total Equity	-$16.6M-149.8%	-$6.7M+48.3%	-$12.9M-182.0%	-$4.6M-201.6%	$4.5M-63.2%	$12.2M-48.9%	$23.9M-26.6%	$32.6M
Retained Earnings	-$408.4M-2.9%	-$396.8M-3.4%	-$383.6M-2.7%	-$373.7M-3.9%	-$359.8M-3.3%	-$348.2M-4.9%	-$332.0M-4.9%	-$316.6M

RCEL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$31.2M+36.3%	-$48.9M-28.7%	-$38.0M-99.1%	-$19.1M+26.3%	-$25.9M-13.9%	-$22.7M
Capital Expenditures	$1.0M-89.0%	$9.2M+564.1%	$1.4M+205.5%	$452K-49.4%	$894K+51.5%	$590K
Free Cash Flow	-$32.2M+44.6%	-$58.1M-47.5%	-$39.4M-101.6%	-$19.5M+27.1%	-$26.8M-14.8%	-$23.3M
Investing Cash Flow	$12.5M-66.7%	$37.4M+2225.0%	$1.6M+108.3%	-$19.3M-1546.7%	-$1.2M-38.6%	-$847K
Financing Cash Flow	$14.9M+325.8%	$3.5M-91.3%	$40.4M+4386.0%	$900K-98.6%	$64.0M-16.9%	$77.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$5.4M-4.2%	-$5.2M+49.0%	-$10.2M+0.8%	-$10.3M-27.6%	-$8.1M-12.0%	-$7.2M+43.6%	-$12.8M+38.7%	-$20.9M
Capital Expenditures	-$674K-172.2%	$934K+78.2%	$524K+137.1%	$221K-86.3%	$1.6M-57.1%	$3.8M+41.8%	$2.7M+131.2%	$1.1M
Free Cash Flow	-$6.1M+0.7%	-$6.2M+42.8%	-$10.8M-2.1%	-$10.5M-8.6%	-$9.7M+11.7%	-$11.0M+28.9%	-$15.4M+29.9%	-$22.0M
Investing Cash Flow	$11K+100.2%	-$5.3M-176.1%	$7.0M-34.8%	$10.8M+335.7%	$2.5M-66.6%	$7.4M-40.5%	$12.4M-17.5%	$15.1M
Financing Cash Flow	$248K-98.2%	$13.8M+2362.6%	$559K+54.0%	$363K-64.4%	$1.0M+1.4%	$1.0M+18.6%	$849K+34.5%	$631K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RCEL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	82.1%-3.7pp	85.9%+1.4pp	84.5%+2.0pp	82.5%+2.8pp	79.7%+0.5pp	79.2%
Operating Margin	-59.4%+28.7pp	-88.1%-3.0pp	-85.1%-5.2pp	-79.9%+10.9pp	-90.8%+208.4pp	-299.2%
Net Margin	-67.8%+28.4pp	-96.3%-25.7pp	-70.6%+6.9pp	-77.5%+13.5pp	-90.9%+203.7pp	-294.7%
Return on Equity	N/A	-1374.6%-1302.5pp	-72.1%-40.6pp	-31.5%-8.5pp	-23.0%+35.1pp	-58.1%
Return on Assets	-86.2%-8.6pp	-77.6%-45.9pp	-31.7%-4.6pp	-27.1%-6.0pp	-21.2%+29.8pp	-51.0%
Current Ratio	0.57-2.3	2.83-5.1	7.88-0.3	8.18-8.2	16.42+6.2	10.17
Debt-to-Equity	0.00-9.4	9.39+8.6	0.81+0.7	0.15+0.1	0.09-0.1	0.14
FCF Margin	-45.0%+45.5pp	-90.4%-11.9pp	-78.6%-21.8pp	-56.8%+34.9pp	-91.7%+72.0pp	-163.6%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	81.2%-0.1pp	81.3%+0.2pp	81.2%-3.5pp	84.7%-2.9pp	87.6%+3.9pp	83.7%-2.4pp	86.1%-0.3pp	86.4%
Operating Margin	-59.1%-5.4pp	-53.6%+6.9pp	-60.5%+3.4pp	-63.9%-9.8pp	-54.1%+16.5pp	-70.6%+32.2pp	-102.8%+52.1pp	-155.0%
Net Margin	-66.0%+11.3pp	-77.3%-23.4pp	-53.9%+21.0pp	-74.9%-11.9pp	-63.0%+19.9pp	-82.9%+18.4pp	-101.3%+66.7pp	-168.0%
Return on Equity	N/A	N/A	N/A	N/A	-257.6%-125.1pp	-132.5%-68.2pp	-64.4%-7.1pp	-57.3%
Return on Assets	-20.6%+0.1pp	-20.7%-3.6pp	-17.1%+2.9pp	-19.9%-5.4pp	-14.5%+5.4pp	-20.0%-2.5pp	-17.5%+1.6pp	-19.2%
Current Ratio	0.57-0.1	0.67+0.1	0.58-1.5	2.09-0.7	2.83-0.9	3.73-1.6	5.29-2.0	7.25
Debt-to-Equity	0.000.0	0.00+3.3	-3.27+5.8	-9.07-18.5	9.39+5.9	3.48+1.8	1.71+0.4	1.27
FCF Margin	-34.7%+1.4pp	-36.1%+22.3pp	-58.4%-1.5pp	-56.9%-4.2pp	-52.7%+3.5pp	-56.1%+45.4pp	-101.6%+96.7pp	-198.2%

Note: Shareholder equity is negative (-$16.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.57), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Profound Med Corp PROF

$215.9M

Rapid Micro Biosystems, Inc. RPID

$100.9M

Sera Prognostics, Inc. SERA

$75.2M

Icad Inc ICAD

$105.8M

Lensar Inc LNSR

$70.1M

Frequently Asked Questions

What is Avita Medical Inc's annual revenue?

Avita Medical Inc (RCEL) reported $71.6M in total revenue for fiscal year 2025. This represents a 11.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Avita Medical Inc's revenue growing?

Avita Medical Inc (RCEL) revenue grew by 11.5% year-over-year, from $64.3M to $71.6M in fiscal year 2025.

Is Avita Medical Inc profitable?

No, Avita Medical Inc (RCEL) reported a net income of -$48.6M in fiscal year 2025, with a net profit margin of -67.8%.

What is Avita Medical Inc's EBITDA?

Avita Medical Inc (RCEL) had EBITDA of -$40.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Avita Medical Inc have?

As of fiscal year 2025, Avita Medical Inc (RCEL) had $10.2M in cash and equivalents against $0 in long-term debt.

What is Avita Medical Inc's gross margin?

Avita Medical Inc (RCEL) had a gross margin of 82.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Avita Medical Inc's operating margin?

Avita Medical Inc (RCEL) had an operating margin of -59.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Avita Medical Inc's net profit margin?

Avita Medical Inc (RCEL) had a net profit margin of -67.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Avita Medical Inc's free cash flow?

Avita Medical Inc (RCEL) generated -$32.2M in free cash flow during fiscal year 2025. This represents a 44.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Avita Medical Inc's operating cash flow?

Avita Medical Inc (RCEL) generated -$31.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Avita Medical Inc's total assets?

Avita Medical Inc (RCEL) had $56.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Avita Medical Inc's capital expenditures?

Avita Medical Inc (RCEL) invested $1.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Avita Medical Inc spend on research and development?

Avita Medical Inc (RCEL) invested $20.8M in research and development during fiscal year 2025.

How many shares does Avita Medical Inc have outstanding?

Avita Medical Inc (RCEL) had 31M shares outstanding as of fiscal year 2025.

What is Avita Medical Inc's current ratio?

Avita Medical Inc (RCEL) had a current ratio of 0.57 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Avita Medical Inc's debt-to-equity ratio?

Avita Medical Inc (RCEL) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Avita Medical Inc's return on assets (ROA)?

Avita Medical Inc (RCEL) had a return on assets of -86.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Avita Medical Inc's cash runway?

Based on fiscal year 2025 data, Avita Medical Inc (RCEL) had $10.2M in cash against an annual operating cash burn of $31.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Avita Medical Inc's debt-to-equity ratio negative or unusual?

Avita Medical Inc (RCEL) has negative shareholder equity of -$16.6M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Avita Medical Inc's Piotroski F-Score?

Avita Medical Inc (RCEL) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Avita Medical Inc's earnings high quality?

Avita Medical Inc (RCEL) has an earnings quality ratio of 0.64x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Avita Medical Inc cover its interest payments?

Avita Medical Inc (RCEL) has an interest coverage ratio of -8.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Avita Medical Inc?

Avita Medical Inc (RCEL) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.